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Objective:
 
 To evaluate the association between drug
therapy patterns achieved with conventional antipsy-
chotics and direct healthcare costs over 2 years.
 
Methods:
 
 Paid claims data from the California Medic-
aid (Medi-Cal) program were used to identify 2476 pa-
tients with schizophrenia for whom 2 years of data
were available. Ordinary least squares (OLS) regression
models were used to estimate the association between
lack of antipsychotic drug therapy, delayed therapy,
changes in medications, and continuous therapy on
healthcare costs over a 2-year period.
 
Results:
 
 Nearly 99% of Medi-Cal patients with schizo-
phrenia were treated with conventional antipsychotics.
Patients with schizophrenia consumed nearly $48,000
in direct costs over 2 years. Over 16% of patients did
not use any antipsychotic medication for 2 years. Un-
treated patients used more healthcare resources than
treated patients did ($10,833, 
 
P
 
 
 

 
 .0422), especially
psychiatric hospital care ($8,027, 
 
P
 
 
 

 
 .0004). How-
ever, treated patients frequently experienced subopti-
mal drug use patterns. Nearly 33% of treated patients
delayed antipsychotic therapy for up to 2 years. De-
layed therapy was associated with increased costs of
$12,285 (
 
P
 
 
 

 
 .070). Over 56% of patients experienced
changes in therapy that were associated with higher to-
tal direct costs ($17,644, 
 
P
 
 
 

 
 .0001). Finally, only
3.2% of treated patients used an antipsychotic medica-
tion consistently for 2 years. However, continuous drug
therapy was not associated with lower costs.
 
Conclusion:
 
 Suboptimal drug use patterns are common
and costly in Medi-Cal patients with schizophrenia who
initiated therapy with conventional antipsychotics.
 
Keywords:
 
antipsychotic drug use patterns, direct med-
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Introduction
 
Schizophrenia is a chronic psychotic disorder that
adversely affects a broad range of psychological
processes, including perception, ideation, affect, at-
tention, concentration, motivation, and judgment.
No single symptom is pathognomonic of schizo-
phrenia and the psychological and behavioral char-
acteristics of the disorder are associated with a vari-
ety of impairments in occupational and social
functioning. Most patients alternate between acute
psychotic episodes and stable periods characterized
by full or partial remission of symptoms [1]. The
disorder affects men and women equally, although
the peak onset for women is later than for men
(late 20s/early 30s vs. early 20s). Overall, the life-
time prevalence of schizophrenia has been esti-
mated at approximately 1% of the population [2].
Despite its relatively low prevalence, the cost of
treating schizophrenia represents a major burden
to the US healthcare system. Rice and Miller [3]
estimated the cost of schizophrenia in the United
States in 1990 to be $32.5 billion, of which $17
billion were direct medical costs. Wyatt et al. [4]
placed the estimated burden at $65 billion in 1991
dollars, while Dickey et al. [5] estimated the direct
cost to the Massachusetts Medicaid Program to
range between $15,000 and $19,600 per patient
per year. These results are not surprising given the
profoundly disabling course of schizophrenia com-
monly experienced by patients [6] and the correla-
tion between schizophrenia and medical illness
[7,8], mortality [2,9–14], and suicide [15–17].
In an earlier study, McCombs et al. [18] docu-
mented the extent to which patients in the Califor-
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nia Medicaid (Medi-Cal) program achieved drug
use patterns indicative of effective drug therapy over
a 1-year period. Medi-Cal patients with schizophre-
nia, treated primarily with conventional antipsy-
chotic medications (98%), did not display patterns
of antipsychotic drug use indicative of successful
drug therapy. First, 24.3% of patients did not use
any antipsychotic medication for at least a year. In
addition, 24.4% of treated patients started or re-
started antipsychotic drug therapy at some point
during the first year. Both results imply patients
with schizophrenia commonly take extended “drug
holidays” when treated in the outpatient setting.
Second, nearly half of patients switched antipsy-
chotic medications or augmented their initial ther-
apy within 1 year.
McCombs et al. [19] estimated the annual direct
healthcare cost of treating schizophrenia at $26,000
per patient based on this sample of Medi-Cal pa-
tients. Delayed antipsychotic drug therapy and
changes in therapy were correlated with increased
direct cost [19]. Equally important, uninterrupted
antipsychotic drug therapy using conventional an-
tipsychotic medications was not associated with re-
duced direct costs, as has been found in studies of
other drug classes and disease states using Medi-
Cal data [20,21].
Drug formulary decision-makers must often de-
cide whether or not to provide unrestricted access
to expensive new medications before adequate
data are available that document the cost-effec-
tiveness of these products in real-world practice.
One key factor in this decision-making environ-
ment with incomplete information is the availabil-
ity of research documenting the effectiveness of
conventional interventions. Specifically, if conven-
tional interventions are found to result in subopti-
mal outcomes, then access to new treatment op-
tions may be warranted, if only on a temporary
basis.
The purpose of this research is to provide data
concerning the effectiveness of conventional anti-
psychotic medications to drug formulary decision-
makers as they consider providing unrestricted ac-
cess to second-generation antipsychotic medications
for patients with schizophrenia. Specifically, this
study builds on previous research [18,19] by evaluat-
ing whether the suboptimal antipsychotic drug use
patterns observed in Medi-Cal patients had a persis-
tent association with increased direct healthcare
costs of treating patients with schizophrenia over a
2-year period. However, while these data are useful
in determining whether a problem exists in the deliv-
ery of effective antipsychotic drug therapy to pa-
tients with schizophrenia, the causes of any observed
patterns of suboptimal therapy cannot be deter-
mined. One hypothesis that resonates well with clini-
cians and is consistent with previous research [2,22]
suggests that patients with schizophrenia may fre-
quently discontinue or otherwise interrupt drug ther-
apy when using conventional antipsychotic medica-
tions, possibly due to extrapyramidal symptoms or
other side effects and/or treatment nonresponse
[17,24]. In presenting our results, we discuss the con-
sistency between our findings and this hypothesis.
This analysis cannot provide any information
concerning the effectiveness of second-generation
antipsychotics in improving antipsychotic drug ther-
apy for Medi-Cal patients with schizophrenia. Dur-
ing the period studied in this analysis, Medi-Cal
restricted the use of second-generation antipsy-
chotic medications by requiring patients to have
failed on two treatment attempts using conven-
tional antipsychotics. The small number of patients
whose first recorded Medi-Cal antipsychotic pre-
scription was for a second-generation antipsy-
chotic is insufficient to investigate the relative ef-
fectiveness of this class of medications.
 
Methods
 
Data Source
 
The data for the analysis were derived from the
Medi-Cal program, which finances a wide range
of healthcare services for the poor and disabled,
including outpatient prescription drugs. The Medi-
Cal program generates a longitudinal research data-
base for a random 5% sample of all recipients for as
long as the sample recipient is eligible [23]. This
database provides patient-level demographic data
combined with a summary of each claim for cov-
ered services paid on behalf of the recipient. Data
include type of service, date of service, amount
billed, amount paid, and units (days) of service.
Prescription drug claims identify the specific prod-
uct dispensed, the quantity and strength of the
drug, and the date the prescription was filled.
Medi-Cal prescriptions were provided subject to a
$1 copayment, though anecdotal information sug-
gests that the copayment is not routinely collected.
Data for this analysis were drawn from the period
January 1987 to July 1996.
 
Cost Definitions
 
Medi-Cal paid claims were partitioned by type of
service for the purpose of estimating costs. For non-
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institutional services, the amount paid by Medi-Cal
understates total payments incurred for elderly and
disabled Medi-Cal recipients who are dually eligi-
ble for Medicare, which becomes the primary payer
for these patients. Missing cost data were estimated
using a methodology based on the amount paid by
Medi-Cal and the Medicare Part B deductible and
coinsurance rate. Actual Medi-Cal expenditures for
noninstitutional services were used for patients un-
der 65 and for services not covered by Medicare
Part B (e.g., prescription drug costs). All reported
noninstitutional expenditures were adjusted to 1996
dollars using Medi-Cal–specific fee schedule adjust-
ments [24].
Medicare is also the primary payer for institu-
tional services used by elderly Medi-Cal recipients.
The amount paid by Medi-Cal for these patients
reflects either the hospital deductible or the days
of nursing home care not covered by Medicare.
Therefore, for simplicity and consistency, the cost
for hospital, skilled nursing facility (SNF), and in-
termediate care facility (ICF) care was estimated
for all patients based on the days of service. Spe-
cifically, days of care were multiplied by the aver-
age per diem cost reported for these services by
Medi-Cal and Medicare. Hospital days were as-
signed a cost of $979 per day [24], while SNF and
ICF costs per day were valued at $270 [25].
Providers rarely recorded diagnostic data on
their Medi-Cal payment claims. However, using
available diagnostic data to identify patients with
schizophrenia for inclusion in this study should
not result in a large number of false positives.
However, missing diagnostic data will result in the
misclassification of patients with schizophrenia as
being free of this disorder. Missing diagnostic data
limited the sample size available for analysis and
may have biased our sample to more severely ill
patients who consume a larger volume of services.
Missing diagnostic data also precluded any at-
tempt to focus the analyses on the cost of providing
schizophrenia-specific services. To address this limi-
tation, the cost of services provided by mental health
providers such as psychologists, community mental
health centers, and psychiatric hospitals or psychiat-
ric hospital wards were compiled and analyzed sepa-
rately. However, a study limited to only schizophre-
nia-specific costs may not be appropriate because
several studies have established a strong correlation
between schizophrenia and other medical conditions
[7,8]. Therefore, this analysis of the direct costs asso-
ciated with schizophrenia also included non-mental-
health-related costs to provide a more comprehen-
sive estimate of the cost of treating patients with
schizophrenia and the impact of antipsychotic drug
therapy patterns on total direct treatment costs.
 
Unit of Observation
 
This analysis defined a single 2-year treatment pe-
riod for Medi-Cal patients with schizophrenia.
The start date of the treatment period was either
the fill date for the patient’s earliest recorded paid
claim for an antipsychotic medication or the date
of service for the earliest recorded paid claim for
which a schizophrenia diagnosis was recorded.
This approach allowed for an analysis of patients
who do not use antipsychotic drugs to treat their
condition. The analysis was designed to estimate
the cost implications of suboptimal antipsychotic
drug use patterns on direct treatment costs over a
2-year period. Suboptimal drug patterns were de-
fined as delays in therapy, changes in therapy, and
interrupted drug therapy during the 2-year treat-
ment period.
 
Inclusion and Exclusion Criteria
 
Patients were selected for study based on their
Medi-Cal paid claims history using the following
inclusion criteria:
1. A diagnosis of schizophrenia recorded on at least
one paid claim or the use of clozapine or risperi-
done. Prior authorization was required by Medi-
Cal for clozapine and risperidone that limited
their use to patients with schizophrenia who had
failed at least two treatment attempts using older
antipsychotics. To further insure that the study
population was limited to patients with schizo-
phrenia, patients selected based solely on risperi-
done use were also required to be under the age
of 50. This reduces the probability of including
patients who may have used this medication to
treat Alzheimer’s disease or dementia.
2. A minimum of 30 days of claims data before
the start of the treatment period.
3. A minimum of 2 years of paid claims data fol-
lowing the initiation of the treatment period to
insure adequate post-treatment data for analysis.
Patients were excluded from the analysis if any
of the following criteria were met:
1. Patient expenditures for “other” services were
over $50,000 per year in either of the first two
post-treatment years. “Other” services consisted
primarily of all paid claims for which the type of
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provider was unknown but also included minor
service categories, such as dental services, that
do not represent a major component in the total
array of services consumed by patients with
schizophrenia.
2. Patients were under age 14 or over 100 at the
start of the treatment period.
3. Patients exhibited gaps in excess of 90 days in
their paid claims data during the 2-year treat-
ment period.
The last exclusion criterion requires explanation.
For most Medi-Cal patients, gaps in their paid
claims history often indicate that they may have lost
Medi-Cal eligibility during the episode of treatment.
However, for schizophrenia patients, such gaps are
more likely to indicate that the patient withdrew
from the Medi-Cal healthcare system for an ex-
tended period despite being eligible for continuous
Medi-Cal coverage. Several types of withdrawal are
possible: incarceration within the criminal justice
system; seeking treatment from an alternative health-
care system, such as Veterans Administration hospi-
tals and clinics; or true withdrawal from all sources
of healthcare.
General population survey data indicate that
substantial proportions of community residents
with schizophrenia and other psychotic disorders
may disengage from the healthcare system for sub-
stantial periods [2,22]. By definition, these pa-
tients with schizophrenia utilize fewer healthcare
resources than patients who engaged the health-
care system on a regular basis.
A total of 1333 (35.0%) patients were found to
have gaps in paid claims in excess of 90 days. These
patients consumed far fewer Medi-Cal healthcare
resources than patients without significant gaps in
their paid claims history and may represent less se-
verely ill patients. However, given the uncertainty
concerning the cause for these gaps in paid claims
history, these patients were excluded from this
analysis. The final study sample consisted of 2476
patients.
 
Antipsychotic Drug Use Patterns
 
This research estimated the impact of four pat-
terns of antipsychotic drug use on direct health-
care cost. These patterns were defined in a manner
consistent with previous research [18,19]. The
treated population consists of all patients with
schizophrenia who received antipsychotic drug ther-
apy at any time within the 2-year treatment period.
Delayed therapy patients are a subset of treated pa-
tients who delayed the onset of antipsychotic drug
therapy for more than 30 days, but not more than 2
years. While the reasons for abstaining from or de-
laying therapy are unknown, the periodic use of an-
tipsychotic medications may reflect patient avoid-
ance of the side effects of conventional antipsychotic
medications until an exacerbation of symptoms re-
quired a restart of antipsychotic drug therapy. Simi-
larly, changes in therapy over a 2-year period may
be common with antipsychotic medications because
of their side-effect profiles and limited efficacy
[26]. A change in therapy was defined as the addi-
tion of a second antipsychotic medication within 2
years, either concomitantly with the patient’s ini-
tial medication or as replacement therapy. Finally,
patients were considered to have completed 2
years of continuous drug therapy if their paid
claims history recorded purchases of any type of
antipsychotic medication without any gaps of 45
or more days between fill dates. While this defini-
tion is consistent with an antipsychotic medication
being consistently available to the patient, it does
not guarantee that the patient either took the med-
ication or complied with its directions for use.
 
Statistical Methods
 
Ordinary least squares (OLS) models were used to
investigate the impact of each of the drug use pat-
terns defined above on total healthcare cost and
the components of total cost over a 2-year treat-
ment period [27]. Models using log-transformed
costs were also estimated to account for the likely
skewness of the sample distribution of costs. A di-
chotomous variable for having received drug ther-
apy during the 2-year treatment period was en-
tered directly into the OLS cost models to estimate
the cost effects of having used an antipsychotic
medication. The effects of delayed therapy, com-
pleted therapy, and changes in therapy were all
measured using interaction terms between these
dichotomous variables and the dichotomous treat-
ment variable. In this way, the effects of each of
these drug use patterns are measured relative to
other treated patients.
As many as 54 independent variables were in-
cluded in these models in addition to dichotomous
variables indicating the patient’s antipsychotic drug
use patterns. These additional independent variables
include the prior use of healthcare, demographic
characteristics, and the patient’s mental and medical
diagnostic mix and psychotropic drug profile at the
start of the treatment period. For brevity, only those
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variables found to have a significant impact on the
dependent variable studied were reported in the
tables that follow.
 
Results
 
Patterns of Antipsychotic Drug Use
 
Figure 1 displays the antipsychotic drug use pat-
terns of the study population. Over 16% (
 
n
 
 
 

 
 408)
of 2476 study patients received no drug therapy
for the 2 years following their first recorded Medi-
Cal service with a schizophrenia diagnosis. The
percentage of patients with no therapy over the
first year was over 21% [18]. This indicates that
many untreated patients did not receive anti-
psychotic drug therapy for extended periods. Fur-
thermore, an additional 32% of patients (
 
n
 
 
 

 
 677)
treated with an antipsychotic medication within 2
years did so after a delay in therapy of at least 30
days. This is also consistent with the hypothesis
that patients may interrupt drug therapy for ex-
tended periods. Finally, over 56% of all patients
treated without a delay in therapy switched thera-
pies or augmented their initial therapy with a sec-
ond antipsychotic medication during the 2-year
treatment period.
 
Descriptive Statistics
 
The patients with schizophrenia in this study (
 
N
 
 
 

 
2476) had a minimum of 2 years of post-treatment
data available for analysis and are a subset of the
patients studied previously [18,19] (
 
N
 
 
 

 
 3321). As
before, these patients were very likely to have other
mental disorders recorded on their paid claims,
especially major depressive disorder (21.0%), bi-
polar disorder (15.4%), anxiety (13.2%), nonor-
ganic psychoses (20.6%), and neurotic depression
(11.4%) (Table 1). Their common use of concom-
itant psychotropic medications, especially antide-
pressants (17.4%), reflected the pattern of con-
comitant psychotropic drug use found in the earlier
study. Patients with schizophrenia who were not
using antipsychotic medications appeared to have
fewer reported comorbid mental disorders than
patients treated with an antipsychotic medication.
Nearly 30% of patients who used an antipsy-
chotic medication also used medications to treat
extrapyramidal symptoms that are hypothesized
here to be a factor in interrupted drug therapy.
Data for the type of antipsychotic drug used are
presented in Table 2 for all treated patients, patients
with delayed therapy, and patients who added a sec-
ond antipsychotic. Overall, drug selection patterns
were similar across all three patient populations:
Haloperidol is the most frequently prescribed initial
medication, followed by thioridazine. There were
no patients who used haloperidol decanoate as ini-
tial therapy. As before, the use of the second-genera-
tion antipsychotics (only clozapine and risperidone
were available during the study period) was limited
to 1.1% overall.
Probably the most significant finding in Table 2
is the relatively small number of schizophrenia pa-
tients (3.2%) who continued to purchase antipsy-
chotic medications for 2 years. This reflects the
average duration of uninterrupted drug therapy of
only 161 days (
 
SD
 
 
 

 
 198 days).
The unadjusted mean total direct cost of treat-
ment for the treated and untreated schizophrenic
patients over 2 years were statistically similar:
$46,270 for treated patients and $55,206 for un-
treated patients (Table 3, 
 
P
 
 
 

 
 .1309). However,
this difference is difficult to interpret given the
data in Tables 1 and 3 that indicate that treated
patients were more likely to have a concomitant
mental health diagnosis recorded on their paid
claims, but were less likely to have used psychiat-
ric hospital care in the pretreatment period.
Figure 1 Patterns of drug usage.
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The mix of services for treated and untreated pa-
tients in the 2-year treatment period was different
in many important respects. Specifically, treated pa-
tients had higher post-treatment expenditures for
prescription drugs and acute hospital and commu-
nity mental health center services. Untreated pa-
tients utilized significantly more psychiatric hospi-
tal services over 2 years ($12,175) compared to
treated patients ($1,443, 
 
P
 
 
 

 
 .05). Similar results
were found after 1 year [19], documenting that dif-
ferences in mix of healthcare services consumed by
treated and untreated patients continued through
 
Table 1
 
Descriptive statistics: demographic, diagnostic, and concomitant drug use data
 
Characteristic
All patients (%)
 
n
 
 
 

 
 2476
Treated patients (%)
 
n
 
 
 

 
 2068
Patients with no drug therapy
 
n
 
 
 

 
 408
Demographic characteristics
Age 44.1 43.4* 47.4*
Gender (% Female) 53.9 53.8 54.7
Urban 81.5 80.7* 85.8*
Concomitant drug use
Prescription narcotics 6.7 5.9* 10.5*
Hypnotics 6.5 6.8 5.1
Anticonvulsants 13.0 12.3* 16.4*
Anti-Parkinsonian drugs 0.7 0.8 0.2
Anti-anxiety drugs 0.8 0.7 1.5
Antidepressants 17.4 17.7 16.2
Anabuse 0.2 0.2 0.0
EPS drugs 25.2 29.9* 1.5*
Used one pharmacy 13.6 11.9* 22.3*
Concomitant Mental Disorders
Dementia 4.9 4.8 5.1
Alcohol or drug abuse 4.0 4.0 3.7
Manic 2.6 2.9* 1.0*
MDD 21.0 21.5* 18.6*
Bipolar 15.4 17.5* 5.1*
Anxiety 13.2 12.6* 16.4*
Nonorganic psychoses 20.6 22.2* 12.3*
Neurotic depression 11.4 10.6* 15.2*
Other neurotic disorders 7.7 8.5* 3.7*
Drug psychoses 6.7 6.4 8.3
Transient organic psychoses 3.7 4.3* 1.0*
Chronic organic psychoses 3.1 3.3 2.0
Other affective disorders 1.5 1.6 1.0
Other mental disorders 32.5 32.5 32.6
 
*Statistically significant difference between treated and untreated populations at 
 
P
 
 
 

 
 .05 using chi-square.
MDD, major depressive disorder.
 
Table 2
 
Antipsychotic drug use
 
Characteristic
All treated patients:
initial therapy
 
n
 
 
 

 
 2,068
Initial therapy in patients
with delayed therapy
 
n
 
 
 

 
 677
Secondary therapy in patients
with added drug
 
n
 
 
 

 
 914
Antipsychotic medications [
 
n
 
(%)]
Haloperidol 520 (25.1) 162 (23.9) 177 (19.4)
Thioridazine 339 (16.4) 124 (18.3) 136 (14.9)
Lithium 197 (9.5) 59 (8.7) 140 (15.3)
Fluphenazine 214 (10.3) 68 (10.0) 80 (8.8)
Thiothixene 190 (9.2) 48 (7.1) 78 (8.5)
Trifluoperazine 187 (9.0) 67 (9.9) 58 (6.3)
Chlorpromazine 157 (7.6) 57 (8.4) 94 (10.3)
Perphenazine 126 (6.1) 44 (6.5) 45 (4.9)
Fluphenazine (dec/eth) 72 (3.5) 30 (4.4) 65 (7.1)
Other antipsychotics 38 (1.8) 11 (1.6) 30 (3.3)
Second-generation antipsychotics (atypicals) 22 (1.1) 7 (1.0) 11 (1.2)
Achieved 2 years of uninterrupted antipsychotic
drug therapy (%)
3.2 0.0 4.3
Total days of uninterrupted drug therapy 161 146 174
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the second post-treatment year. The sharp differ-
ences in psychiatric hospital costs may reflect pa-
tients having been admitted to state psychiatric
hospitals when the antipsychotic drug costs were
included in the hospital payment from Medi-Cal. If
this is true, these data also indicate that patients
discharged from state facilities do not continue
their inpatient drug therapy upon their return to
the community.
 
Multivariate Statistical Results
 
Table 4 presents the results of the OLS model of
total direct healthcare costs over the 2-year treat-
ment period. Active drug therapy was associated
with a significant reduction in total direct cost of
nearly $11,000 over the 2-year period. However,
delays in drug therapy and changes in therapy
were associated with significantly higher total di-
rect healthcare costs of $12,285 and $17,644, re-
spectively, while continuous purchases of an an-
tipsychotic medication for 2 years did not have a
significant effect on the direct costs of care.
The OLS models of cost by type of service (Table
5) shed some light on these cost results. Having re-
ceived antipsychotic drug therapy appeared to sig-
nificantly reduce a patient’s use of psychiatric hospi-
tal care over the 2-year treatment period (
 

 
$8027).
 
Table 3
 
Treatment cost: 30 days prior and 2 years post
 
Characteristics
All patients ($)
 
n
 
 
 

 
 2476
Treated patients ($)
 
n
 
 
 

 
 2068
Patients with no drug therapy ($)
 
n
 
 
 

 
 408
30 days prior to episode
Outpatient (Part B) 466 445 567
Psychologist 14 12* 26*
Prescription drugs 52 51 50
Community mental health center 34 35 26
Dental 13 14 10
Other services 8 8 4
Acute hospital use [
 
n
 
(%)] 157 (6.3%) 137 (6.6%) 20 (4.9%)
Acute hospital cost 669 688 571
Psychiatric hospital use [
 
n
 
(%)] 26 (1.1%) 21 (1.0%) 5 (1.2%)
Psychiatric hospital cost 151 117 321
Nursing home use [
 
n
 
(%)] 23 (0.9%) 17 (0.8%) 6 (1.5%)
Nursing home cost 147 128 238
Total costs prior 30 days 885 814* 1,243*
2 years post-treatment
Outpatient (Part B) 11,804 11,294 14,392
Psychologist 315 311 336
Prescription drugs 2,094 2,200* 1,558*
Community mental health center 712 783* 353*
Dental 472 467 499
Other services 645 657 584
Acute hospital cost 9,424 10,010 6,452
Psychiatric hospital cost 3,212 1,443* 12,175*
Nursing home cost 19,064 19,105 18,857
Total healthcare costs 47,742 46,270 55,206
 
*Statistically significant difference between treated and untreated patients at 
 
P
 
 
 

 
 .05.
 
Table 4
 
Factors significantly affecting the total cost of 
healthcare in the 2-year treatment period, 
 
N
 
 
 

 
 2476 
(adjusted 
 
R
 
2
 
 
 

 
 .2420)
 
Independent variable Estimated effect
 
P
 
 value
Prior use of health services
($/mo)
Acute hospital 5.29 .0001
Psychiatric hospital 12.41 .0001
Nursing home care 8.36 .0001
Demographic characteristics
Age (months) 96.23 .0001
Used one pharmacy 17,913 .0002
Diagnostic profile 
(mental health)
Bipolar disorder
 

 
9,644 .0411
Chronic organic psychoses 48,782 .0001
Dementia 34,082 .0001
Other neurotic disorders 19,021 .0023
Paranoia 21,200 .0370
Nonorganic psychoses 8,772 .0347
Diagnostic profile 
(medical conditions)
Trauma/injury 14,210 .0001
Angina
 

 
22,276 .0094
Muscle disorders
 

 
9,131 .0114
Congestive heart failure 23,396 .0073
Received antipsychotic
drug therapy
 

 
10,833 .0422
Delayed drug therapy
during first 2 years 12,285 .0070
Switch or augmented 
drug therapy 17,644 .0001
Completed 2 years of 
uninterrupted therapy 221 .9647
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Conversely, delayed therapy and changes in therapy
are correlated with significantly higher acute hospi-
tal costs of $6859 and $5500, respectively. Changes
in therapy and continuous therapy were also corre-
lated with higher nursing home costs ($8687, 
 
P
 
 
 

 
.0004; $5606, 
 
P
 
 
 

 
 .0469, respectively). However,
the monitoring of drug therapy in the nursing home
may have caused uninterrupted therapy and changes
in therapy rather than these drug use patterns
“causing” increased nursing home costs. There-
fore, these effects on nursing home costs should be
interpreted with caution.
The pattern of cost effects at 2 years is consis-
tent with estimated effects at 1 year reported else-
where [19]. Active drug therapy further reduced
the use of psychiatric inpatient care from 
 

 
$2846
at 1 year to 
 

 
$8027 over 2 years. Delayed ther-
apy was associated with an increase in acute hos-
pital costs from 
 

 
 $5210 at 1 year to 
 

 
 $6859
over 2 years. Similarly, changes in therapy were
correlated with an increase in the use of acute hos-
pital services from 
 

 
 $3050 at 1 year to 
 

 
 $5550
over 2 years. The increase in estimate cost effects
when measured over 2 years suggests that these ef-
fects and/or the drug use patterns that caused
them were persistent over time.
Table 6 displays the results of the OLS analysis
of log-transformed costs. The pattern of effects is
generally consistent with the OLS results on actual
costs. Delayed therapy correlates with significant
increases in use of services in all except Other Ser-
vices. Changes in therapy are associated with in-
creased acute hospital costs, ambulatory service
use, drug cost, and total costs. Having received
antipsychotic drug therapy is no longer associated
with statistically significant changes in costs, with
the exception of drug costs, although the sign of
the impact of receiving drug therapy on the com-
ponents of costs is consistent with OLS results.
Completed therapy was associated only with in-
creased drug costs.
The OLS models explain a statistically signifi-
cant proportion of the total variance in the health-
care costs experienced by Medi-Cal schizophrenia
patients (
 
R
 
2
 
s ranging from .1095 for ambulatory
services to .3270 for psychiatric hospital care).
Furthermore, age and prior use of institutional
services correlated highly with future costs. Both
results attest to the robustness of the models, re-
flecting the validity of the results presented here.
 
Discussion
 
The purpose of this research was to provide for-
mulary decision-makers with information to guide
their decisions concerning making second-genera-
tion antipsychotic medications available without
restrictions to patients with schizophrenia. Specifi-
cally, this research was intended to document the
extent to which suboptimal antipsychotic drug use
patterns exist in this population and to estimate
the direct costs associated with these patterns of
suboptimal drug use patterns over a 2-year period.
 
Table 5
 
The effect of drug therapy patterns on healthcare costs—summary of 2-year effect by type of service, 
 
N  2476
Total
R2  .2420
Acute hospital
R2  .1694
Psychiatric hospital
R2  .3270
Nursing home
R2  .3234
Ambulatory 
R2  .1095
Drugs
R2  .2646
Other
R2  .2102
Received drug therapy 10,833* 1,590 8,027* 1,752 3,109 220 327
Delayed drug therapy 12,285* 6,859* 334 862 3,517 481* 209
Switched/augmented 17,644* 5,500* 1,181 8,687* 1,423 576* 228
Completed 2 years of 
uninterrupted therapy 221 2,563 1,394 5,606* 1,737 345* 173
*Statistically significant estimated cost effect at P  .05.
Table 6 The effect of drug therapy patterns on healthcare costs—summary of log-transformed cost results by type of 
service, N  2476
Total
R2  .03111
Acute hospital
R2  .2538
Psychiatric hospital
R2  .1853
Nursing home
R2  .2569
Ambulatory
R2  .3399
Drugs 
R2  .3300
Other
R2  .2489
Received drug therapy 0.148 0.146 0.063 0.213 0.103 1.091* 0.120
Delayed drug therapy 0.355* 1.018* 0.325* 0.844* 0.208*
0.265* 0.430
Switched/augmented 0.438* 1.413* 0.109 1.215* 0.187*
0.276* 0.159
Completed 1 year 
uninterrupted therapy 0.114 0.397 0.082 0.415 0.012 0.473* 0.152
*Statistically significant estimated cost effect at P  .05.
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To be truly effective, antipsychotic drug therapy
for patients with schizophrenia should be main-
tained without interruption for long periods. The
results presented here clearly document that Medi-
Cal patients treated primarily with conventional
antipsychotic medications did not achieve this goal.
First, 16% of Medi-Cal patients with schizophrenia
did not use any antipsychotic medication for at
least 2 years. Second, one-third of patients ap-
peared to restart therapy within the 2-year study
period. Moreover, a majority of patients (56%)
who received antipsychotic drug therapy switched
or augmented their therapy within the 2-year pe-
riod. Finally, only 3.2% of Medi-Cal patients who
used an antipsychotic medication continued to pur-
chase these medications consistently for 2 years, a
decrease from a 13% continuation rate at 1 year
[18]. The average duration of uninterrupted ther-
apy for treated patients was 161 days. These results
are particularly distressing because the patients in-
cluded in this study were fully engaged in the Medi-
Cal healthcare system, having never exceeded 90
days without at least one paid claim for care.
Schizophrenia is an expensive disease to treat in
terms of direct medical care costs. The cost to
Medi-Cal was nearly $48,000 per patient over the
2-year period studied here. The previous analysis
estimated first-year costs at nearly $26,000 per
patient [19]; therefore, the costs of treating schizo-
phrenia do not appear to abate over time. The re-
sults reported here also found that the use of an-
tipsychotic medications was associated with lower
direct healthcare costs, especially psychiatric hos-
pital costs. However, conventional antipsychotic
medications also exhibited frequent suboptimal
drug use patterns that were associated with in-
creased costs over time relative to earlier 1-year
results [19]. Therefore, it appears that few patients
were able to achieve the full benefits of conven-
tional antipsychotic drug therapy.
The results reported here suggest that strategies
must be developed to address the frequency with
which suboptimal antipsychotic drug use patterns
occur for patients with schizophrenia. These data
also suggest that any intervention that is successful
in improving drug therapy may achieve significant
offsetting savings. Specifically, the intervention
must reduce the rate at which patients abstain from
or delay antipsychotic drug therapy, or switch be-
tween alternative antipsychotic medications over
time. Potential cost offsets could extend over multi-
ple years if new therapies prove effective over ex-
tended periods of treatment. One potential strategy
now facing formulary decision-makers is to provide
unrestricted access to second-generation antipsy-
chotic medications as initial therapy. While these
medications have shown promise in clinical trials,
very little data are available on their effectiveness in
real-world clinical practice. However, the underly-
ing problem with antipsychotic drug therapy re-
ported here may not be related to efficacy or side
effects of conventional antipsychotic medications.
If the existence of suboptimal drug use patterns is
due primarily to factors such as the patient’s un-
willingness to accept their illness or inability to un-
derstand the need for long-term drug therapy, then
access to new medications may also fail to meet the
therapeutic needs of patients with schizophrenia.
The Medi-Cal program added second-generation
antipsychotic medications to its formulary in the
fall of 1997, based in part on its review of the data
presented here. However, any decision by a health-
care system to provide access to interventions with
limited cost-effectiveness data must be reevaluated
over time. Ideally, the healthcare system should use
its own data to test the cost-effectiveness of its deci-
sion to expand access as part of the reevaluation
process. Such a follow-up study is now underway.
The results reported here must be viewed with
caution because of possible biases introduced by the
exclusion of patients with gaps in their Medi-Cal
paid claims history. This excluded population likely
includes Medi-Cal–eligible patients with schizophre-
nia who were functioning well enough to have suc-
cessfully withdrawn from all forms of healthcare ser-
vices for at least one 90-day period during the 2-year
treatment period defined for each patient. If so, total
cost of care estimates reported here are biased up-
ward. Conversely, our estimate that 3.2% of patients
complete a minimum of 2 years of uninterrupted
drug therapy is also biased upward because the ex-
cluded patients would, by definition, have experi-
enced a break in drug therapy in excess of 45 days.
The population of patients excluded based on a
90-day gap in all paid claims is also likely to in-
clude homeless persons and persons incarcerated
in the criminal justice system. While these patients
are less costly from the perspective of the Medi-Cal
budget, they may be more severely psychotic than
the average patient with schizophrenia. But more
important, the societal cost associated with these
patients may be quite high in terms of housing,
criminal justice system costs, and the like. Other
patients with gaps in their paid claims history may
be less severely ill or in extended remission. Still
others may have better social and family support
systems that reduce the patient’s risk for relapse
and help maintain physical health. These “disen-
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gaged” patients with schizophrenia are truly less
costly than the patients included in this analysis.
This research was supported by a grant from Eli Lilly and
Company, Indianapolis, IN.
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